Shots:
- Oculis has completed pts enrollment in both P-III (DIAMOND-1 & DIAMOND-2) trials of OCS-01 in diabetic macular edema pts; trials to support NDA submission
- The trials will evaluate the efficacy & safety of OCS-01 in over 800 pts with DME across 119 sites in the US & other countries for 52wks.; topline data is expected in Q2’26, followed by regulatory submissions
- OCS-01 is a high-dose dexamethasone eye drop, developed using Oculis’ Optireach tech as a non-invasive retinal treatment for DME
Ref: Globenewswire | Image: Oculis
Related News:- Oculis Reports Results from P-II (ACUITY) Study of OCS-05 for Treating Acute Optic Neuritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
